{"id":"https://openalex.org/W4327608409","doi":"https://doi.org/10.1227/neu.0000000000002375_866","title":"866 Preclinical Study of Pamiparib, a CNS Penetrant PARP Inhibitor, in IDH1/2 Mutated Gliomas","display_name":"866 Preclinical Study of Pamiparib, a CNS Penetrant PARP Inhibitor, in IDH1/2 Mutated Gliomas","publication_year":2023,"publication_date":"2023-03-15","ids":{"openalex":"https://openalex.org/W4327608409","doi":"https://doi.org/10.1227/neu.0000000000002375_866"},"language":"en","primary_location":{"id":"doi:10.1227/neu.0000000000002375_866","doi":"https://doi.org/10.1227/neu.0000000000002375_866","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1227/neu.0000000000002375_866","pdf_url":null,"source":{"id":"https://openalex.org/S111727011","display_name":"Neurosurgery","issn_l":"0148-396X","issn":["0148-396X","1081-1281","1524-4040"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurosurgery","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045750934","display_name":"Christopher Sungwoon Hong","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Christopher Sungwoon Hong","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016318219","display_name":"Ranjini K. Sundaram","orcid":"https://orcid.org/0000-0002-5725-0284","observed_orcids":["https://orcid.org/0000-0002-5725-0284"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ranjini Sundaram","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5040738951","display_name":"Ranjit S. Bindra","orcid":"https://orcid.org/0000-0002-3255-0467","observed_orcids":["https://orcid.org/0000-0002-3255-0467"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ranjit Bindra","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.03446899,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"69","issue":"Supplement_1","first_page":"45","last_page":"46"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.8076000213623047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","score":0.8076000213623047,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10129","display_name":"Glioma Diagnosis and Treatment","score":0.18979999423027039,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10123","display_name":"DNA Repair Mechanisms","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pamiparib","display_name":"pamiparib","score":1.0},{"id":"https://openalex.org/keywords/parp-inhibitors","display_name":"PARP inhibitors","score":0.8399999737739563},{"id":"https://openalex.org/keywords/idh1-mutant-glioma","display_name":"IDH1-mutant glioma","score":0.8140000104904175},{"id":"https://openalex.org/keywords/homologous-recombination-deficiency","display_name":"homologous recombination deficiency","score":0.828000009059906},{"id":"https://openalex.org/keywords/2-hydroxyglutarate","display_name":"2-hydroxyglutarate","score":0.9620000123977661},{"id":"https://openalex.org/keywords/temozolomide","display_name":"temozolomide","score":0.9480000138282776},{"id":"https://openalex.org/keywords/radiotherapy","display_name":"radiotherapy","score":0.5180000066757202},{"id":"https://openalex.org/keywords/drug-synergy","display_name":"drug synergy","score":0.6690000295639038},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.7319999933242798},{"id":"https://openalex.org/keywords/brain-penetration","display_name":"brain penetration","score":0.6740000247955322},{"id":"https://openalex.org/keywords/poly-adp-ribosyl-ation","display_name":"poly(ADP-ribosyl)ation","score":0.4909999966621399},{"id":"https://openalex.org/keywords/mgmt","display_name":"MGMT","score":0.5669999718666077}],"concepts":[{"id":"https://openalex.org/C2778227246","wikidata":"https://www.wikidata.org/wiki/Q1365309","display_name":"Glioma","level":2,"score":0.64188152551651},{"id":"https://openalex.org/C207583985","wikidata":"https://www.wikidata.org/wiki/Q128723","display_name":"Wild type","level":4,"score":0.5844884514808655},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.5483145117759705},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.5249060392379761},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4791914224624634},{"id":"https://openalex.org/C53227056","wikidata":"https://www.wikidata.org/wiki/Q189152","display_name":"Viability assay","level":3,"score":0.46748799085617065},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4670863151550293},{"id":"https://openalex.org/C128473837","wikidata":"https://www.wikidata.org/wiki/Q7863603","display_name":"U87","level":3,"score":0.45650750398635864},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4122244119644165},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.4109748899936676},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.40549105405807495},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.27236294746398926},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.13074448704719543},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.07326701283454895},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1227/neu.0000000000002375_866","doi":"https://doi.org/10.1227/neu.0000000000002375_866","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1227/neu.0000000000002375_866","pdf_url":null,"source":{"id":"https://openalex.org/S111727011","display_name":"Neurosurgery","issn_l":"0148-396X","issn":["0148-396X","1081-1281","1524-4040"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurosurgery","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3215187145","https://openalex.org/W3083477970","https://openalex.org/W2900416837","https://openalex.org/W4245066261","https://openalex.org/W2740705488","https://openalex.org/W4415272165","https://openalex.org/W2767973856","https://openalex.org/W4388590749","https://openalex.org/W2588147230","https://openalex.org/W2985601929"],"abstract_inverted_index":{"INTRODUCTION:":[0],"Our":[1],"group":[2],"demonstrated":[3,152,199],"IDH1/2-mutated":[4,36,252],"gliomas":[5,37,253],"harbor":[6],"intrinsic":[7,263],"homologous":[8],"recombination":[9],"(HR)":[10],"defects":[11],"mediated":[12],"by":[13,125],"2-HG,":[14],"conferring":[15],"sensitivity":[16,101,108,137],"to":[17,41,102,147,195,219,261],"PARP-inhibitors.":[18],"We":[19,46],"studied":[20],"pamiparib,":[21,215],"a":[22,132],"CNS-penetrant":[23],"PARP-inhibitor":[24],"with":[25,31,51,67,73,170,188,203,207,242,257],"potent":[26],"PARP-trapping":[27],"ability,":[28],"in":[29,35,86,112,131,140,155,172,182,192],"combination":[30],"TMZ":[32,107,151,166,258],"and":[33,38,54,58,80,90,143,150,174,190,210,230,254,259],"radiation":[34,191,260],"its":[39],"pharmacokinetics":[40],"demonstrate":[42],"CNS":[43,201,269],"penetrance.":[44],"METHODS:":[45],"performed":[47],"DNA-repair":[48],"functional":[49],"studies":[50,60],"in-vitro":[52],"short-":[53],"long-term":[55],"viability":[56,84],"assays,":[57],"in-vivo":[59],"utilizing":[61],"an":[62],"intracranial":[63,223],"rat":[64],"glioma":[65],"model":[66],"bioluminescence":[68],"imaging.":[69],"Pharmacokinetics":[70,198,266],"was":[71,109,138,168,186],"measured":[72],"LCMS/MS":[74],"from":[75],"harvested":[76],"tumor,":[77],"normal":[78,240,243],"brain,":[79],"blood.":[81],"RESULTS:":[82],"In-vitro":[83],"assays":[85],"paired":[87],"isogenic":[88],"IDH1-wildtype":[89],"mutant":[91,175,183],"U87":[92,142,156],"cells":[93,145,176],"showed":[94],"the":[95,128],"IDH1":[96,160],"mutation":[97,161],"conferred":[98],"several-fold":[99],"enhanced":[100],"TMZ,":[103],"as":[104,115],"expected.":[105],"Differential":[106],"less":[110],"pronounced":[111],"HCT116":[113,144,164],"cells,":[114,157,165],"expected":[116],"given":[117],"higher":[118],"MGMT":[119],"expression.":[120],"ELISA":[121],"confirmed":[122],"PARylation":[123],"inhibition":[124],"pamiparib":[126,136,171,189],"at":[127,179],"nanomolar":[129],"range":[130],"dose-dependent":[133],"manner.":[134],"Enhanced":[135],"seen":[139],"IDH-mutant":[141],"compared":[146,194],"wildtype.":[148],"Pamiparib":[149,235,248],"synergistic":[153],"interactions":[154],"dependent":[158],"upon":[159],"status.":[162],"In":[163],"resistance":[167],"overcome":[169],"wildtype":[173,196],"but":[177],"notably":[178],"lower":[180],"doses":[181,213],"cells.":[184,197],"Synergy":[185],"observed":[187],"U87-mutant,":[193],"favorable":[200,268],"penetration":[202,270],"tumor:plasma":[204],"ratios":[205,245],"(>0.20)":[206],"3":[208],"mg/kg":[209,212],"6":[211],"of":[214],"orally":[216],"administered":[217],"BID":[218,272],"rats":[220],"harboring":[221],"RG2-cell":[222],"tumors.":[224],"These":[225],"levels":[226],"persisted":[227],"between":[228],"2-":[229],"8-hours":[231],"after":[232,271],"last":[233],"dosing.":[234],"selectively":[236,250],"penetrated":[237],"tumors":[238],"over":[239],"brain":[241],"brain:plasma":[244],"<0.20.":[246],"CONCLUSIONS:":[247],"may":[249],"target":[251],"act":[255],"synergistically":[256],"exploit":[262],"HR":[264],"defects.":[265],"suggest":[267],"oral":[273],"administration.":[274]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-03-17T00:00:00"}